{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T13:10:08Z","timestamp":1788527408476,"version":"build-2803163510"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T00:00:00Z","timestamp":1745798400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T00:00:00Z","timestamp":1745798400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100017539","name":"Theodor Bilharz Research Institute","doi-asserted-by":"publisher","award":["113 D"],"award-info":[{"award-number":["113 D"]}],"id":[{"id":"10.13039\/100017539","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017539","name":"Theodor Bilharz Research Institute","doi-asserted-by":"publisher","award":["113 D"],"award-info":[{"award-number":["113 D"]}],"id":[{"id":"10.13039\/100017539","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017539","name":"Theodor Bilharz Research Institute","doi-asserted-by":"publisher","award":["113 D"],"award-info":[{"award-number":["113 D"]}],"id":[{"id":"10.13039\/100017539","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017539","name":"Theodor Bilharz Research Institute","doi-asserted-by":"publisher","award":["113 D"],"award-info":[{"award-number":["113 D"]}],"id":[{"id":"10.13039\/100017539","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017539","name":"Theodor Bilharz Research Institute","doi-asserted-by":"publisher","award":["113 D"],"award-info":[{"award-number":["113 D"]}],"id":[{"id":"10.13039\/100017539","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017539","name":"Theodor Bilharz Research Institute","doi-asserted-by":"publisher","award":["113 D"],"award-info":[{"award-number":["113 D"]}],"id":[{"id":"10.13039\/100017539","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017539","name":"Theodor Bilharz Research Institute","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100017539","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:sec>\n            <jats:title>Background<\/jats:title>\n            <jats:p>Carbapenem resistant <jats:italic>Pseudomonas aeruginosa<\/jats:italic> (<jats:italic>P. aeruginosa<\/jats:italic>) is a global health concern that poses a challenge to treat in health care facilities. Ceftazidim\/avibactam and ceftolozane\/tazobactam have a potential role in treatment of multi-drug resistant phenotypes including carbapenem resistant <jats:italic>P. aeruginosa.<\/jats:italic> Therefore, we aimed to assess the in vitro antimicrobial activity of ceftazidime\/avibactam and ceftolozane\/tazobactam against carbapenem-resistant <jats:italic>P. aeruginosa<\/jats:italic> (CRPA) strains with different \u03b2-lactamase\/carbapenemase genes.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Sixty CRPA isolates identified from clinical samples were examined for antimicrobial susceptibility including ceftazidim\/avibactam and ceftolozane\/tazobactam by Vitek2 compact system, and carbapenemase production by modified carbapenem inactivation method (mCIM) test and carbapenemase producing genes by polymerase chain reaction (PCR).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Isolates were resistant to imipenem in 96.7% and meropenem in 88.3%. of isolates. Carbapenemase production by mCIM test was 70% compared to 73.3% by (PCR).<\/jats:p>\n            <jats:p>Carbapenemase encoding genes <jats:italic>bla<\/jats:italic>\n              <jats:sub>NDM<\/jats:sub>, <jats:italic>bla<\/jats:italic>\n              <jats:sub>VIM<\/jats:sub> and <jats:italic>bla<\/jats:italic>\n              <jats:sub>OXA-48<\/jats:sub> were detected in 60%, 41.7% and 25% respectively while <jats:italic>bla<\/jats:italic>\n              <jats:sub>IMP<\/jats:sub> and <jats:italic>bla<\/jats:italic>\n              <jats:sub>KPC<\/jats:sub> weren\u2019t identified in this study. Among CRPA, both ceftazidim\/avibactam and ceftolozane\/tazobactam; were sensitive in only 11.7% of the isolates. Resistance to ceftazidim\/avibactam and ceftolozane\/tazobactam in isolates owning <jats:italic>bla<\/jats:italic>\n              <jats:sub>NDM<\/jats:sub>, <jats:italic>bla<\/jats:italic>\n              <jats:sub>VIM<\/jats:sub>, <jats:italic>bla<\/jats:italic>\n              <jats:sub>OXA-48<\/jats:sub> and those having combined <jats:italic>bla<\/jats:italic>\n              <jats:sub>NDM<\/jats:sub>, <jats:italic>bla<\/jats:italic>\n              <jats:sub>VIM<\/jats:sub> and <jats:italic>bla<\/jats:italic>\n              <jats:sub>OXA-48<\/jats:sub> carbapenemase resistance genes were 97.2%, 92%, 100% and 100% respectively.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusion<\/jats:title>\n            <jats:p>Modified carbapenem inactivation method test gave satisfactory results and could be used as an alternative to expensive genotypic methods. Ceftazidim\/avibactam and ceftolozane\/tazobactam were unsuccessful against carbapenem resistant <jats:italic>P. aeruginosa<\/jats:italic> isolates carrying carbapenemase genes especially metallo-\u03b2 lactamase genes. Therefore, it is essential to detect susceptibility patterns to newly introduced \u03b2-Lactam\/\u03b2-Lactamase inhibitor combinations due to the emerging resistance to these therapeutics.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1186\/s12879-025-10891-w","type":"journal-article","created":{"date-parts":[[2025,4,28]],"date-time":"2025-04-28T21:15:46Z","timestamp":1745874946000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Assessment of in vitro antimicrobial activities of ceftolozane\/tazobactam and ceftazidime\/avibactam against carbapenem-resistant\u00a0Pseudomonas\u00a0aeruginosa clinical isolates"],"prefix":"10.1186","volume":"25","author":[{"given":"Dalia","family":"Salem","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"El-Shenawy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heba","family":"Dahroug","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manar","family":"Zaiton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doaa","family":"Gamal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manal","family":"Diab","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,28]]},"reference":[{"issue":"18","key":"10891_CR1","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1007\/s40265-021-01635-6","volume":"81","author":"D Reynolds","year":"2021","unstructured":"Reynolds D, Kollef M. The Epidemiology and Pathogenesis and Treatment of Pseudomonas aeruginosa Infections: an update. Drugs. 2021;81(18):2117\u201331. https:\/\/doi.org\/10.1007\/s40265-021-01635-6.","journal-title":"Drugs"},{"issue":"14","key":"10891_CR2","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.2147\/idr.s298920","volume":"24","author":"A El-Kholy","year":"2021","unstructured":"El-Kholy A, El-Mahallawy HA, Elsharnouby N, Abdel Aziz M, Helmy AM, Kotb R. Landscape of multidrug-resistant gram-negative infections in egypt: survey and literature review. Infect Drug Resist. 2021;24(14):1905\u201320. https:\/\/doi.org\/10.2147\/idr.s298920.","journal-title":"Infect Drug Resist"},{"issue":"2","key":"10891_CR3","doi-asserted-by":"publisher","first-page":"e0200021","DOI":"10.1128\/AAC.02000-21","volume":"66","author":"YL Lee","year":"2022","unstructured":"Lee YL, Ko WC, Hsueh PR. Geographic Patterns of Carbapenem-Resistant Pseudomonas aeruginosa in the Asia-Pacific Region: Results from the Antimicrobial Testing Leadership and Surveillance (ATLAS) Program, 2015\u20132019. Antimicrob Agents Chemother. 2022;66(2):e0200021. https:\/\/doi.org\/10.1128\/AAC.02000-21.","journal-title":"Antimicrob Agents Chemother"},{"key":"10891_CR4","doi-asserted-by":"publisher","unstructured":"Hazirolan G, And Ozkul C. \"Evaluation of in Vitro Activity of Ceftolozane\/Tazobactam and Ceftazidime\/Avibactam Against Carbapenem-Resistant Pseudomonas aeruginosa Strains and Mechanisms of Carbapenem Resistance: Data from Tertiary Care Hospital. Jundishapur J Microbiol. 2023;16(3). https:\/\/doi.org\/10.5812\/jjm-134090","DOI":"10.5812\/jjm-134090"},{"issue":"3","key":"10891_CR5","doi-asserted-by":"publisher","first-page":"894","DOI":"10.21608\/mid.2023.220134.1555","volume":"4","author":"S Fayed","year":"2023","unstructured":"Fayed S, Mohammed M, Khashaba R, El-Kholy A. Susceptibility of multi-drug resistant isolates of Pseudomonasaeruginosa\u00a0to ceftazidime\/aviabactam and ceftolozane\/tazobactam in Benha University Hospital in Egypt and detection of carbapenemase genes. Microb Infect Dis. 2023;4(3):894\u2013904. https:\/\/doi.org\/10.21608\/mid.2023.220134.1555.","journal-title":"Microb Infect Dis"},{"issue":"4","key":"10891_CR6","doi-asserted-by":"publisher","first-page":"238","DOI":"10.21608\/aprh.2022.142365.1177","volume":"6","author":"A Azzam","year":"2022","unstructured":"Azzam A, Khaled H, Hesham M. The Prevalence of Metallo-\u03b2-Lactamase-Producing Pseudomonas aeruginosa in Egypt: A Systematic Review and Meta-Analysis. J Adv Pharm Res. 2022;6(4):238\u201348. https:\/\/doi.org\/10.21608\/aprh.2022.142365.1177.","journal-title":"J Adv Pharm Res."},{"issue":"1","key":"10891_CR7","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1080\/22221751.2022.2048972","volume":"11","author":"FC Tenover","year":"2022","unstructured":"Tenover FC, Nicolau DP, Gill CM. Carbapenemase-producing Pseudomonas aeruginosa -an emerging challenge. Emerg Microbes Infect. 2022;11(1):811\u20134. https:\/\/doi.org\/10.1080\/22221751.2022.2048972.","journal-title":"Emerg Microbes Infect"},{"issue":"12","key":"10891_CR8","doi-asserted-by":"publisher","first-page":"e01858","DOI":"10.1128\/AAC.01858-17","volume":"61","author":"RM Humphries","year":"2017","unstructured":"Humphries RM, Hindler JA, Wong-Beringer A, Miller SA. Activity of Ceftolozane-Tazobactam and Ceftazidime-Avibactam against Beta-Lactam-Resistant Pseudomonas aeruginosa Isolates. Antimicrob Agents Chemother. 2017;61(12):e01858-17. https:\/\/doi.org\/10.1128\/AAC.01858-17.","journal-title":"Antimicrob Agents Chemother."},{"key":"10891_CR9","unstructured":"Clinical and Laboratory Standards Institute (CLSI) 2023. Performance standards for antimicrobial susceptibility testing M100 33rd ed. 2023. Wayne, PA."},{"key":"10891_CR10","unstructured":"Sambrook J, Fritsch EF, Maniatis T. Molecular cloning: a laboratory manual (Glycerol shock), In: Zahlreiche S, editor, vol 16, 2nd edn. 1989. Cold Spring Harbor Laboratory Press, pp 32\u20135"},{"issue":"12","key":"10891_CR11","doi-asserted-by":"publisher","first-page":"4592","DOI":"10.1128\/jcm.01765-10","volume":"48","author":"PG Higgins","year":"2010","unstructured":"Higgins PG, Lehmann M, Wisplinghoff H, Seifert H. gyrB multiplex PCR to differentiate between Acinetobacter calcoaceticus and Acinetobacter genomic species 3. J Clin Microbiol. 2010;48(12):4592\u20134. https:\/\/doi.org\/10.1128\/jcm.01765-10.","journal-title":"J Clin Microbiol"},{"key":"10891_CR12","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.ijid.2015.12.003","volume":"43","author":"D Gamal","year":"2016","unstructured":"Gamal D, Fern\u00e1ndez-Mart\u00ednez M, Salem D, El-Defrawy I, Alvares Montes L, Ocampo-Sosa A, Mart\u00ednez-Mart\u00ednez L. Carbapenem-resistant Klebsiella pneumoniae isolates from Egypt containing blaNDM-1 on IncR plasmids and its association with rmtF. Int J Infect Dis. 2016;43:17\u201320. https:\/\/doi.org\/10.1016\/j.ijid.2015.12.003.","journal-title":"Int J Infect Dis"},{"issue":"1","key":"10891_CR13","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.diagmicrobio.2010.12.002","volume":"70","author":"L Poirel","year":"2011","unstructured":"Poirel L, Walsh TR, Cuvillier V, Nordmann P. Multiplex PCR for detection of acquired carbapenemase genes. Diagn Microbiol Infect Dis. 2011;70(1):119\u201323. https:\/\/doi.org\/10.1016\/j.diagmicrobio.2010.12.002.","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"2","key":"10891_CR14","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.jcma.2017.08.016","volume":"81","author":"S Rostami","year":"2018","unstructured":"Rostami S, Farajzadeh Sheikh A, Shoja S, Farahani A, Tabatabaiefar MA, Jolodar A, et al. Investigating of four main carbapenem-resistance mechanisms in high-level carbapenem resistant Pseudomonas aeruginosa isolated from burn patients. J Chin Med Assoc. 2018;81(2):127\u201332. https:\/\/doi.org\/10.1016\/j.jcma.2017.08.016.","journal-title":"J Chin Med Assoc"},{"key":"10891_CR15","doi-asserted-by":"publisher","first-page":"e00031","DOI":"10.1128\/cmr.00031-19","volume":"32","author":"J Horcajada","year":"2019","unstructured":"Horcajada J, Montero M, Oliver A, Sorl\u00ed L, Luque S, G\u00f3mez-Zorrilla S, et al. Epidemiology and Treatment of Multidrug-Resistant and Extensively Drug-Resistant Pseudomonas aeruginosa Infections. Clin Microbiol Rev. 2019;32:e00031-e119. https:\/\/doi.org\/10.1128\/cmr.00031-19.","journal-title":"Clin Microbiol Rev"},{"key":"10891_CR16","doi-asserted-by":"publisher","first-page":"2141","DOI":"10.2147\/IDR.S182777","volume":"11","author":"R El-Sokkary","year":"2018","unstructured":"El-Sokkary R, Ramadan R, El-Shabrawy M, El-Korashi L, Elhawary A, Embarak S, et al. Community acquired pneumonia among adult patients at an egyptian university hospital: bacterial etiology, susceptibility profile and evaluation of the response to initial empiric antibiotic therapy. Infect Drug Resist. 2018;11:2141\u201350. https:\/\/doi.org\/10.2147\/IDR.S182777.","journal-title":"Infect. Drug Resist"},{"key":"10891_CR17","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s42269-020-00350-8","volume":"44","author":"A Basha","year":"2020","unstructured":"Basha A, El-Sherbiny G, Mabrouk M. Phenotypic characterization of the Egyptian isolates \u201cextensively drug-resistant\u00a0Pseudomonasaeruginosa\u201d and detection of their metallo-\u03b2-lactamases encoding genes. Bull Natl Res Cent. 2020;44:117. https:\/\/doi.org\/10.1186\/s42269-020-00350-8.","journal-title":"Bull Natl Res Cent"},{"issue":"1","key":"10891_CR18","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1186\/s42269-020-00350-8","volume":"66","author":"A Gaballah","year":"2018","unstructured":"Gaballah A, Elbaradei A, Elsheredy A, Kader O. Emergence of blaVEB and blaGES among VIM producing Pseudomonas aeruginosa clinical isolates in Alexaneria. Egypt Acta Microbiol Immunol Hung. 2018;66(1):131\u201342. https:\/\/doi.org\/10.1186\/s42269-020-00350-8.","journal-title":"Egypt Acta Microbiol Immunol Hung"},{"issue":"1","key":"10891_CR19","doi-asserted-by":"publisher","first-page":"100351","DOI":"10.1016\/j.jgeb.2024.100351","volume":"22","author":"FA Afify","year":"2024","unstructured":"Afify FA, Shata AH, Aboelnaga N, Osama D, Elsayed SW, Saif NA, et al. Emergence of carbapenem resistant gram-negative pathogens with high rate of colistin resistance in Egypt: a cross sectional study to assess resistance trends during the COVID-19 pandemic. J Genet Eng Biotechnol. 2024;22(1):100351. https:\/\/doi.org\/10.1016\/j.jgeb.2024.100351.","journal-title":"J Genet Eng Biotechnol"},{"issue":"3","key":"10891_CR20","doi-asserted-by":"publisher","first-page":"693","DOI":"10.21608\/mid.2022.142569.1320","volume":"3","author":"E Khater","year":"2022","unstructured":"Khater E, Alfaki A. Detection of carbapenem-resistant\u00a0Pseudomonas aeruginosa\u00a0in tertiary care hospital in Saudi Arabia. Microb Infect Dis. 2022;3(3):693\u2013702. https:\/\/doi.org\/10.21608\/mid.2022.142569.1320.","journal-title":"Microb Infect Dis"},{"key":"10891_CR21","doi-asserted-by":"publisher","first-page":"525","DOI":"10.3390\/antibiotics12030525","volume":"12","author":"A Gondal","year":"2023","unstructured":"Gondal A, Choudhry N, Bukhari H, Rizvi Z, Jahan S, Yasmin N. Estimation, evaluation and characterization of carbapenem resistance burden from a tertiary care hospital. Pakistan Antibiotics. 2023;12:525. https:\/\/doi.org\/10.3390\/antibiotics12030525.","journal-title":"Pakistan Antibiotics"},{"key":"10891_CR22","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1016\/j.jgar.2019.01.032","volume":"18","author":"A Acar","year":"2019","unstructured":"Acar A, Karaahmetoglu G, Akalin H, Altay AF. Pooled prevalence and trends of antimicrobial resistance in Pseudomonas aeruginosa clinical isolates over the past 10 years in Turkey: a meta-analysis. J Glob Antimicrob Resist. 2019;18:64\u201370. https:\/\/doi.org\/10.1016\/j.jgar.2019.01.032.","journal-title":"J Glob Antimicrob Resist"},{"key":"10891_CR23","unstructured":"World Health Organization European Region (WHO\/ Europe). Surveillance of antimicrobial resistance in Europe, 2022 data: WHO\/Europe; 2023 https:\/\/www.ecdc.europa.eu\/sites\/default\/files\/documents\/Nov2023-ECDC-WHO-Executive-Summary.pdf. Accessed Nov 2023."},{"issue":"5","key":"10891_CR24","doi-asserted-by":"publisher","first-page":"1896","DOI":"10.21037\/jtd.2019.05.13","volume":"11","author":"SS Almarzoky Abuhussain","year":"2019","unstructured":"Almarzoky Abuhussain SS, Sutherland CA, Nicolau DP. In vitro potency of antipseudomonal \u03b2-lactams against blood and respiratory isolates of P. aeruginosa collected from US hospitals. J Thorac Dis. 2019;11(5):1896\u2013902. https:\/\/doi.org\/10.21037\/jtd.2019.05.13.","journal-title":"J Thorac Dis"},{"issue":"4","key":"10891_CR25","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1515\/labmed-2019-0162","volume":"44","author":"W Wang","year":"2020","unstructured":"Wang W, Wang X. Prevalence of metallo-\u03b2-lactamase genes among Pseudomonas aeurginosa isolated from various clinical samples in China. J Lab Med. 2020;44(4):197\u2013203. https:\/\/doi.org\/10.1515\/labmed-2019-0162.","journal-title":"J Lab Med"},{"issue":"10","key":"10891_CR26","doi-asserted-by":"publisher","first-page":"1861","DOI":"10.3201\/eid2510.181699","volume":"25","author":"YY Hu","year":"2019","unstructured":"Hu YY, Cao JM, Yang Q, Chen S, Lv HY, Zhou HW, Wu Z, Zhang R. Risk Factors for Carbapenem-Resistant Pseudomonas aeruginosa, Zhejiang Province. China Emerg Infect Dis. 2019;25(10):1861\u20137. https:\/\/doi.org\/10.3201\/eid2510.181699.","journal-title":"China Emerg Infect Dis"},{"issue":"1","key":"10891_CR27","doi-asserted-by":"publisher","first-page":"2639","DOI":"10.1038\/s41598-023-29590-0","volume":"13","author":"M Pottier","year":"2023","unstructured":"Pottier M, Gravey F, Castagnet S, Auzou M, Langlois B, Gu\u00e9rin F, Giard JC, L\u00e9on A, Le Hello S. A 10-year microbiological study of Pseudomonas aeruginosa strains revealed the circulation of populations resistant to both carbapenems and quaternary ammonium compounds. Sci Rep. 2023;13(1):2639. https:\/\/doi.org\/10.1038\/s41598-023-29590-0.","journal-title":"Sci Rep"},{"issue":"4","key":"10891_CR28","doi-asserted-by":"publisher","first-page":"160","DOI":"10.21608\/mjmr.2022.270692","volume":"33","author":"A Saedii","year":"2022","unstructured":"Saedii A, Ahmed A, Mohamed O. Carbapenem resistant strains of pseudomonas species at Minia university hospitals. Minia J Med Res. 2022;33(4):160\u20135. https:\/\/doi.org\/10.21608\/mjmr.2022.270692.","journal-title":"Minia J Med Res"},{"issue":"3","key":"10891_CR29","doi-asserted-by":"publisher","first-page":"13","DOI":"10.21608\/ejmm.2023.298797","volume":"32","author":"A Elsawy","year":"2023","unstructured":"Elsawy A, Al-Quthami K, Abbas A, Khan H, Hanawi W, Hanawi N, et al. Detection of carbapenemase genes and other resistance mechanisms in carbapenem-resistant\/cephalosporin-susceptible Pseudomonas aeruginosa. Egypt J Med Microbiol. 2023;32(3):13\u20138. https:\/\/doi.org\/10.21608\/ejmm.2023.298797.","journal-title":"Egypt J Med Microbiol"},{"issue":"11","key":"10891_CR30","doi-asserted-by":"publisher","first-page":"3079","DOI":"10.1093\/jac\/dkx253","volume":"72","author":"F Schaumburg","year":"2017","unstructured":"Schaumburg F, Bletz S, Mellmann A, Becker K, Idelevich E. Susceptibility of MDR Pseudomonas aeruginosa to ceftolozane\/tazobactam and comparison of different susceptibility testing methods. J Antimicrob Chemoth. 2017;72(11):3079\u201384. https:\/\/doi.org\/10.1093\/jac\/dkx253.","journal-title":"J Antimicrob Chemoth"},{"key":"10891_CR31","doi-asserted-by":"publisher","first-page":"2777","DOI":"10.1093\/jac\/dky267","volume":"73","author":"K Kazmierczak","year":"2018","unstructured":"Kazmierczak K, de Jonge B, Stone G, Sahm D. In vitro activity of ceftazidime\/avibactam against isolates of Pseudomonas aeruginosa collected in European countries: INFORM global surveillance 2012\u201315. J Antimicrob Chemother. 2018;73:2777\u201385. https:\/\/doi.org\/10.1093\/jac\/dky267.","journal-title":"J Antimicrob Chemother"},{"key":"10891_CR32","doi-asserted-by":"publisher","unstructured":"Nasser M, Gayen S, Kharat A. Prevalence of the beta-lactamase and antibiotic resistant Pseudomonas aeruginosa in the Arab Region. J Glob Antimicrob Resist. 2020; https:\/\/doi.org\/10.1016\/j.jgar.2020.01.011","DOI":"10.1016\/j.jgar.2020.01.011"},{"key":"10891_CR33","doi-asserted-by":"publisher","unstructured":"Karlowsky J., Lob S., Siddiqui F., Akrich B, DeRyke A., Young K. et al. In vitro activity of ceftolozane\/tazobactam against multidrug-resistant Pseudomonas aeruginosa from patients in Western Europe: SMART 2017\u20132020, Intern J Antimicrob Agents, 2023; 61(5). https:\/\/doi.org\/10.1016\/j.ijantimicag.2023.106772","DOI":"10.1016\/j.ijantimicag.2023.106772"},{"key":"10891_CR34","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1016\/j.jgar.2020.04.017","volume":"22","author":"E Hirsch","year":"2020","unstructured":"Hirsch E, Brigman H, Zucchi P, Chen A, Jadyn C, Anderson J, et al. Ceftolozane-tazobactam and ceftazidime-avibactam activity against \u03b2-lactam-resistant Pseudomonas aeruginosa and extended-spectrum \u03b2-lactamase-producing Enterobacterales clinical isolates from U.S. medical centres. J Glob Antimicrob Resis. 2020;22:689\u201394. https:\/\/doi.org\/10.1016\/j.jgar.2020.04.017.","journal-title":"J Glob Antimicrob Resis"},{"key":"10891_CR35","doi-asserted-by":"publisher","unstructured":"Lisboa LF, Turnbull L, Boyd DA, Mulvey MR, Dingle TC. Evaluation of a Modified Carbapenem Inactivation Method for Detection of Carbapenemases in Pseudomonas aeruginosa. J Clin Microbiol. 2017;56(1). https:\/\/doi.org\/10.1128\/JCM.01234-17","DOI":"10.1128\/JCM.01234-17"},{"issue":"8","key":"10891_CR36","doi-asserted-by":"publisher","first-page":"2321","DOI":"10.1128\/jcm.00193-17","volume":"55","author":"VM Pierce","year":"2017","unstructured":"Pierce VM, Simner PJ, Lonsway DR, RoeCarpenter DE, Johnson JK, Brasso WB, et al. Modified Carbapenem Inactivation Method for Phenotypic Detection of Carbapenemase Production among Enterobacteriaceae. J Clin Microbiol. 2017;55(8):2321\u201333. https:\/\/doi.org\/10.1128\/jcm.00193-17.","journal-title":"J Clin Microbiol"},{"key":"10891_CR37","doi-asserted-by":"publisher","first-page":"614058","DOI":"10.3389\/fmicb.2021.614058","volume":"12","author":"EJ Yoon","year":"2021","unstructured":"Yoon EJ, Jeong SH. Mobile Carbapenemase Genes in Pseudomonas aeruginosa [Internet]. Front Microbiol. 2021;12:614058. https:\/\/doi.org\/10.3389\/fmicb.2021.614058.","journal-title":"Front Microbiol"},{"issue":"12","key":"10891_CR38","doi-asserted-by":"publisher","first-page":"2533","DOI":"10.1007\/s10096-021-04308-0","volume":"40","author":"CM Gill","year":"2021","unstructured":"Gill CM, Aktathorn E, Alfouzan W, Bourassa L, Brink A, Burnham CD, et al. The ERACE-PA global surveillance program: Ceftolozane\/tazobactam and ceftazidime\/avibactam in vitro activity against a global collection of carbapenem-resistant pseudomonas aeruginosa. Eur J Clin Microbiol Infect Dis. 2021;40(12):2533\u201341. https:\/\/doi.org\/10.1007\/s10096-021-04308-0.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"10891_CR39","doi-asserted-by":"publisher","unstructured":"Wise G, Karlowsky JA, Mohamed N, Hermsen ED, Kamat S, Townsend A, et al. Global trends in carbapenem- and difficult-to-treat-resistance among World Health Organization priority bacterial pathogens: ATLAS surveillance program 2018\u20132022. 2024;37:168\u201375. https:\/\/doi.org\/10.1016\/j.jgar.2024.03.020","DOI":"10.1016\/j.jgar.2024.03.020"},{"issue":"11","key":"10891_CR40","doi-asserted-by":"publisher","first-page":"1325","DOI":"10.3390\/antibiotics10111325","volume":"10","author":"A Mohamed","year":"2021","unstructured":"Mohamed A, Daef E, Nafie A, Shaban L, Ibrahim M. Characteristics of Carbapenem-Resistant Gram-Negative Bacilli in Patients with Ventilator-Associated Pneumonia. Antibiotics (Basel). 2021;10(11):1325. https:\/\/doi.org\/10.3390\/antibiotics10111325.","journal-title":"Antibiotics (Basel)"},{"issue":"3","key":"10891_CR41","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1007\/s10096-019-03761-2","volume":"39","author":"DM Ghaith","year":"2020","unstructured":"Ghaith DM, Zafer MM, Said HM, Elanwary S, Elsaban S, Al-Agamy MH, et al. Genetic diversity of carbapenem-resistant Klebsiella Pneumoniae causing neonatal sepsis in intensive care unit, Cairo. Egypt Eur J Clin Microbiol Infect Dis. 2020;39(3):583\u201391. https:\/\/doi.org\/10.1007\/s10096-019-03761-2.","journal-title":"Egypt Eur J Clin Microbiol Infect Dis"},{"key":"10891_CR42","doi-asserted-by":"publisher","unstructured":"Shah S, Kline E, Haidar G, Squires K, Pogue J, McCreary E et al. Rates of Resistance to Ceftazidime-Avibactam and Ceftolozane-Tazobactam Among Patients Treated for Multidrug-Resistant\u00a0Pseudomonas aeruginosa\u00a0Bacteremia or Pneumonia. Clin Infect Dis. 2024:ciae332.\u00a0https:\/\/doi.org\/10.1093\/cid\/ciae332","DOI":"10.1093\/cid\/ciae332"},{"issue":"3","key":"10891_CR43","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1093\/jpids\/piz002","volume":"8","author":"PD Tamma","year":"2019","unstructured":"Tamma PD, Hsu AJ. Defining the role of novel beta-lactam agents that target carbapenem-resistant Gram-negative organisms. J Pediatric Infect Dis Soc. 2019;8(3):251\u201360. https:\/\/doi.org\/10.1093\/jpids\/piz002.","journal-title":"J Pediatric Infect Dis Soc"},{"key":"10891_CR44","unstructured":"Ramirez P, Merino E, Sarda J, et al. Real-world effectiveness and safety of cefiderocol in patients with Gram-negative bacterial infections in the early access program in Spain: results of the PERSEUS study. Abstract. ECCMID 2024"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-10891-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-025-10891-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-025-10891-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,29]],"date-time":"2025-04-29T09:04:50Z","timestamp":1745917490000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-025-10891-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,28]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["10891"],"URL":"https:\/\/doi.org\/10.1186\/s12879-025-10891-w","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,28]]},"assertion":[{"value":"21 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The protocol of work was approved by institutional review board (FWA00010609), and the work has been carried out in accordance with the Code of Ethics of the World Medical Association (Declaration of Helsinki) for Experiments in Humans. The Research Ethics Committee of Theodor Bilharz Research Institute waived informed consent as working was carried out on unidentified isolates. Patients data and hospital details were anonymized by using codes instead of identifying information.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"622"}}